X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Vafseo (vadadustat) is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It is approved for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.
Lead Product(s): Vadadustat
Therapeutic Area: Nephrology Product Name: Vafseo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Akebia Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
Ferinject (ferric carboxymaltose) is an Fe modulator, small molecule drug candidate. It is approved for the treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Ferinject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
Filspari (sparsentan) is a once-daily oral medication, designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II). It is approved for the treatment of IgA Nephropathy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Travere Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
Ferinject (ferric carboxymaltose) is an iron replacement medicine, used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body. Iron is needed to produce the red blood cells that carry oxygen around your body.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Ferinject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
Kapruvia® (difelikefalin) is a selective kappa opioid receptor agonist with low central nervous system penetration. It is recommended by NICE for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.
Lead Product(s): Difelikefalin
Therapeutic Area: Nephrology Product Name: Kapruvia
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: CARA Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
Filspari (sparsentan) is an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with IgAN. It is being investigated for focal segmental glomerulosclerosis.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Travere Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a, blocking neutrophil activation and migration. Currently being developed for the treatment of ANCA-associated vasculitis.
Lead Product(s): Avacopan,Rituximab
Therapeutic Area: Rare Diseases and Disorders Product Name: Tavneos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a, blocking neutrophil activation and migration. Currently being developed for the treatment of ANCA-associated vasculitis.
Lead Product(s): Avacopan,Rituximab
Therapeutic Area: Immunology Product Name: Tavneos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
Ferinject 50mg/ml Solution for Injection is an iron replacement medicine, used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body. Iron is needed to produce the red blood cells that carry oxygen around your body.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Ferinject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
Kapruvia® (difelikefalin) will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Product Name: Kapruvia
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: CARA Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
